Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $79.7 million.

  • Immunocore Holdings' Non-Current Assets rose 116.72% to $79.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $317.9 million, marking a year-over-year increase of 1950.72%. This contributed to the annual value of $55.9 million for FY2024, which is 90.25% up from last year.
  • As of Q3 2025, Immunocore Holdings' Non-Current Assets stood at $79.7 million, which was up 116.72% from $80.1 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Non-Current Assets registered a high of $80.1 million during Q2 2025, and its lowest value of $52.8 million during Q4 2022.
  • In the last 4 years, Immunocore Holdings' Non-Current Assets had a median value of $67.9 million in 2024 and averaged $68.5 million.
  • As far as peak fluctuations go, Immunocore Holdings' Non-Current Assets skyrocketed by 90.25% in 2024, and later soared by 2042.37% in 2025.
  • Immunocore Holdings' Non-Current Assets (Quarter) stood at $52.8 million in 2022, then increased by 4.95% to $55.4 million in 2023, then rose by 0.9% to $55.9 million in 2024, then soared by 42.49% to $79.7 million in 2025.
  • Its Non-Current Assets was $79.7 million in Q3 2025, compared to $80.1 million in Q2 2025 and $79.4 million in Q1 2025.